PTBP2

Across TCGA pan-cancer cohorts, PTBP2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PTBP2 data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PTBP2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PTBP2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

CCRCC, UCEC, and GBM are the cancer types where PTBP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	III,IV	0.823	0.582	.011	13	view →
UCEC	OS	Median	II,III,IV	0.590	1.000	.007	8	view →
GBM	DFS	Quartile	All	0.804	0.716	.040	3	view →
PDAC	DFS	Tertile	All	0.519	0.324	.046	2	view →
LUAD	DFS	Tertile	All	1.000	0.726	.020	2	view →
LSCC	DFS	Tertile	All	1.000	0.848	.031	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PTBP2–CCRCC (OS)

Open the CCRCC breakdown →